Skip to main content
Equibles
INDP logo

INDP · Indaptus Therapeutics, Inc.

Track INDP — free

Use INDP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INDP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.22 +0.06 (+1.90%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result of these uncertainties, there is substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$421.05M
Shares
133.24M
Volume · Oct 21 528.99K Avg daily vol (3M) 883.12K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.16 Open$2.93 Day$2.85–3.28 52W close$0.94–4.75 Avg vol 30d803K Short int822K · 0.6% float · 1.0d Short vol60% DataJan 2020–Oct 2026 Filing10-Q · Aug 13

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$15.42M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$11.55M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+20,099.4%
Year over year · more shares
Price change (1Y)
-12.0%
Trailing year
Short interest
0.6%
Latest settlement · 1.0 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 16.7 · calm Equity put/call 0.52
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +39%
above
Price vs 50-day avg +41%
above
RSI (14) 58
neutral
MACD trend Positive
52-week position 58%
mid-range
Momentum
relative strength
Strong
1-month return −16%
trailing
6-month return +13%
trailing
YTD return +9%
this year
Relative strength +5%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+50% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.62% of float · ▼ -10.3% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
9 holders — mid 3-yr range
Squeeze score 51
elevated · 0–100
Fundamentals
Fair
EPS growth +52%
Y/Y
Free cash flow $-14.8M
Quant / Vol
risk profile
Very High
Volatility 205%
annualized · 1-yr
Max drawdown −80%
past year
ATR 12.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+39% Bullish
Price vs 50-day avg
+41% Bullish
RSI (14)
58 Neutral
MACD trend
Positive Bullish
52-week position
58% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+50% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.62% of float · ▼ -10.3% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
9 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $3 · 58% Range high $5
vs 200-day avg +39% vs 50-day avg +41%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
INDP
Indaptus Therapeutics, Inc.
this stock
$421.05M +8.6% — — 0.6%
VRTX
Vertex Pharmaceuticals Inc
 $131.39B +15.7% +46.2% 30.2 1.8%
MRNA
Moderna, Inc.
 $98.14B +733.5% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.95B +4.4% +20.8% 20.0 2.1%
CSLLY
Csl Ltd
 $66.22B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
9
% held
0.3%
Net QoQ
+314.4K sh
Top holder
HRT FINANCIAL LP
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Falling
Shares short
822.3K
Days to cover
1.0d
Change
-94.1K sh
View
Short Volume
Short vol %
60%
As of
Oct 21, 2026
Short Total
View
Fails to Deliver
FTD shares
4.9K
Value
$13.9K
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
52.4%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-20.8M
EPS diluted
$-21.58
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 30, 2026
This year
28
View
Exempt Offerings
Offering
$5.0M
Filed
Jun 20, 2025
View

Performance

5D 20D 120D MTD YTD
INDP +43.0% -16.2% +12.9% +37.4% +8.6%
SPY +0.5% +0.7% +7.6% +1.4% +13.4%
vs SPY +42.5% -16.9% +5.3% +36.0% -4.8%
Key facts CIK 1857044 CUSIP 45339J204 Visit website